Skip to Content

Akouos, Inc.

Merger

  • Date:
  • 10/18/2022
  • Company Name:
  • Akouos, Inc.
  • Stock Symbol:
  • AKUS
  • Company Name - Buyer:
  • Eli Lilly and Company
  • Stock Symbol - Buyer:
  • LLY
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/18/2022

Case Finder

Locate any case using the tools below.

NEW YORK, October 18, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Akouos, Inc. (NASDAQ: AKUS) (“Akouos”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Eli Lilly and Company (NYSE: LLY) (“Lilly”).

On October 18, 2022, Archaea announced that it had entered into an agreement to be acquired by Lilly in a cash and contingent value right transaction deal valued at $610 million. Pursuant to the merger agreement, Lilly will acquire all of the outstanding shares of Akouos for $12.50 per share in cash, plus one contingent value right (CVR) of up to $3.00 per share. The deal is expected to close in the fourth quarter of 2022.

Bragar Eagel & Squire is concerned that Akouos’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Akouos’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Akouos. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: